Kite Pharma adds manufacturing assets with T-Cell Factory acquisition

Biotech Kite Pharma ($KITE), which has become a force in cancer immunotherapy, has added some more manufacturing capabilities to the operations it has been beefing up. The Santa Monica, CA company said it would get access to European clinical manufacturing facilities as part of its $21 million acquisition of T-Cell Factory B.V., a private Dutch company that is working on T cell receptor (TCR) technology, FierceBiotech reports. It announced the deal Wednesday. Kite, which has earned a reputation in CAR-T therapies, last month leased two manufacturing facilities near its Southern California base to manufacture its pipeline therapies. One is devoted to commercial production. Story | More

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.